N-acylated GHRH(1-44) analogue
A 44-amino-acid GHRH analogue with a trans-3-hexenoyl moiety attached to the N-terminus for enhanced enzymatic stability.
| Compound | Tesamorelin |
| Research category | GHRH / Secretagogue Research |
| Available sizes | 2mg, 5mg, 10mg, 20mg |
| Pricing | From £55 |
| Format | Lyophilised powder in sealed vial & pre-reconstituted pen |
| Purity | >99% by HPLC (Janoshik Analytical, batch-verified) |
| Intended use | In-vitro laboratory research only. Not for human consumption. |
Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.
| Compound class | Synthetic GHRH(1-44) analogue with N-terminal hexenoyl modification |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.9 g/mol |
| CAS Registry Number | 218949-48-5 |
| PubChem CID | 16133824 |
| Number of residues | 44 |
| Amino acid sequence | trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 |
| Receptor / mechanism | GHRH receptor agonist (1-44 fragment). |
| Reported half-life | Reported ~25–40 minutes in human serum. |
| Solubility | Lyophilised powder reconstitutes in bacteriostatic water for laboratory use. |
| Storage (lyophilised) | Stable at 2–8 °C lyophilised for 24+ months. |
| Storage (reconstituted) | Reconstituted: store at 2–8 °C, use within 14 days. |
| Clinical / regulatory status | Approved by FDA (2010) for HIV-associated lipodystrophy research applications. |
Tesamorelin is a synthetic GHRH analogue comprising the 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoyl modification. Supplied as lyophilised powder for in-vitro research use only.
The above describes how this compound is characterised in the published peer-reviewed literature. It is not a claim about effects in humans.
Tesamorelin is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.
Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration.
| State | Temperature | Shelf life |
|---|---|---|
| Lyophilised | 2–8 °C or −20 °C | Up to 24 months |
| Reconstituted | 2–8 °C | 4–6 weeks typical |
Every batch of Tesamorelin we supply is independently HPLC-verified by Janoshik Analytical. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.
Latest Janoshik report for Tesamorelin 10mg · task #231376 · analysed 29 Sep 2026
This report is for the batch, not the size. Janoshik’s HPLC test measures what the compound is and how pure it is, and its quantification confirms the amount in the vial tested. Every size of Tesamorelin is filled from the same tested batch, so this 10mg report covers 20mg and 30mg as well. The report supplied with your order carries a verification key you can check on Janoshik’s own site.
| Purity | 98.241% |
| Measured content | 10.36 mg |
| Batch | L77tsm2612 |
| Verification key | 2UVDAUP7Q6HR |
Researchers working with Tesamorelin often work alongside the following compounds in the preclinical literature:
References are independent peer-reviewed sources. Lab77 Peptides is not affiliated with these publications.